Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Must-Attempt Fascinating Dishes from Around the World - 2Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- 3Find the Standards of Viable Refereeing: Settling Debates with Strategy
- 4Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- 5Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- Believe Should Unwind? Look at These Scaled down Games
- SF Chinatown's historic Empress of China building being revived into cultural campus
- 4 injured in shooting at North Carolina tree lighting ceremony
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
